A recent UK court ruling broke new ground in ordering an official health body to issue guidelines on prescribing a generic drug. Could the same thing happen in Australia?
Regulation of generics
The Therapeutic Goods Administration (TGA) is the Australian regulatory body for therapeutic goods, including medicines. A generic medicine can be supplied only if the TGA considers there to be evidence showing that the generic medicine is bioequivalent to the original medicine. Before either an original or a generic medicine can be registered in the Register of Therapeutic Goods, the TGA must approve a summary of the scientific information relevant to the use of the medicine, supplied by the registering company. This summary is known as a ‘product information document’, and it is intended that this information be available to assist doctors, pharmacists and other health professionals in prescribing and dispensing medicines.
In recent times, product information documents have become a focus in legal battles between originators of medicines and their generic counterparts. Notably, decisions issued by the High Court and the Full Federal Court have offered guidance to generic pharmaceutical manufacturers on how to avoid contributory patent infringement by amending product information documents.
A recent UK High Court order went a step further by effectively compelling those who prescribe and dispense medicines to enforce a patent owned by a pharmaceutical originator. This may prove to be a game changer in terms of how generic medicines are prescribed and dispensed, and may have implications in Australia.
Use of ‘skinny labelling’ to avoid patent infringement
When patent protection for a reference medicine expires, sometimes patent protection for new indications (ie, new uses of the medicine) can be obtained independently. From the perspective of a generics manufacturer, the medicine per se can be made without the risk of infringement. However, when seeking registration of the medicine with the TGA, if it were mandatory to include every new indication in the product information document the generics manufacturer would arguably be liable for patent infringement.
In reality, Australian law provides generics manufacturers with the option of varying product information documents to exclude indications covered by patents that are in force. Such practice is often referred to as ‘carving out’ specific indications or ‘skinny labelling’.
Apotex v Sanofi (leflunomide)
"High Court affirms that methods of treatment are still patentable in Australia" reported on the significance of the High Court's decision in Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd ( HCA 50) in relation to the patentability of methods of medical treatment in Australia.
The decision also deals with contributory patent infringement. Specifically, Apotex had proposed to supply generic leflunomide for the treatment of psoriatic arthritis and rheumatoid arthritis. However, it had carved out from the corresponding product information document the use of leflunomide in treating psoriasis not associated with symptoms of arthritis. In the court’s view, this was sufficient to avoid infringement of a claim directed to a method of treating or preventing psoriasis patented by Sanofi.
Australian Lyrica decision: Warner-Lambert v Apotex
Following this decision, it might have been assumed that adopting a skinny labelling strategy would provide a clear path to avoid patent infringement. However, this turned out not to be the case, as highlighted by the subsequent unanimous Full Federal Court decision in Warner-Lambert Company LLC v Apotex Pty Ltd ( FCAFC 59).
Warner-Lambert (a member of the Pfizer group) owned an Australian patent for treating pain using the pharmaceutical pregabalin. Pfizer Inc, the parent of the Pfizer group, was co-owner of an Australian patent which covered the use of pregabalin in the treatment of seizures. Pfizer promoted pregabalin in Australia under the trademark LYRICA in relation to the pain indication.
Apotex registered many products containing generic pregabalin in the Register of Therapeutic Goods in respect of the treatment of neuropathic pain and seizures, and sought to invalidate the above patents. While Apotex’s challenge to the patent covering the treatment of seizures was resolved through confidential negotiations, it continued to pursue revocation of the patent covering the pain indication. Apotex amended only some of its registrations for generic pregabalin and the associated product information documents to exclude the pain indication. Other registrations and associated product information documents were not amended. This included registrations/documents linking generic pregabalin to products carrying the brand names of recognised Australian pharmacies (in particular, Terry White Chemists and ChemMart). Further, Apotex intended to apply to list these other pregabalin-containing products in the Pharmaceutical Benefits Scheme (PBS) so that the products would be available to consumers at a subsided price.
Warner-Lambert subsequently commenced infringement proceedings and sought interlocutory relief restraining Apotex from listing its generic pregabalin in the PBS or supplying its pregabalin-containing products. At first instance (Warner-Lambert Company LLC v Apotex Pty Ltd  FCA 241) the Federal Court granted an interlocutory injunction restraining Apotex from supplying products containing pregabalin indicated for the treatment of neuropathic pain. However, the primary judge was not satisfied that Warner-Lambert had demonstrated a case for additional interlocutory relief restraining Apotex from supplying any product containing pregabalin.
Warner-Lambert appealed to the Full Federal Court, which found in Warner-Lambert’s favour as it had reason to believe that Apotex’s generic pregabalin would be used to treat pain based on the size of the pain market compared to the seizure market, even though the pain indication had been carved out. Apotex submitted that it intended to advise doctors and pharmacists not to use generic pregabalin to treat pain; however, this was not persuasive. Consequently, the Full Federal Court extended the injunction to cover all of Apotex’s products containing generic pregabalin.
UK Lyrica decision: Warner-Lambert v Actavis
Similarly to Apotex, Actavis was a generics manufacturer that sought to make generic pregabalin. Actavis also sought to revoke Warner-Lambert’s European patent for pregabalin which covers the treatment of pain (albeit indirectly, because claims directed to methods of treatment are not patentable in Europe). Initially, Actavis planned to market its generic pregabalin under a skinny label in respect of seizures and anxiety disorders (not pain) while it challenged the validity of Warner-Lambert’s European patent.
Warner-Lambert subsequently applied to the High Court of England and Wales for an interim injunction to ensure that Actavis’ generic pregabalin would not be prescribed for pain. The judge recognised that Actavis had taken steps to avoid having its generic pregabalin prescribed for pain (eg, by offering to write to prescribing and dispensing authorities to provide instructions that generic pregabalin is not to be prescribed for pain). Ultimately, the judge in that case (Warner-Lambert Company, LLC v Actavis Group Ptc EHF  EWHC 72 (Pat)) refused the application for an injunction based on the steps taken by Actavis to avoid infringement. However, Warner-Lambert was still concerned that generic pregabalin would be ultimately prescribed for pain. In this regard, the judge noted that the best solution was for the National Health Service (NHS) to issue appropriate guidance to doctors to prescribe Warner-Lambert’s Lyrica for pain. Warner-Lambert then sought and obtained a court order to compel the NHS to issue guidance to doctors and pharmacies that pregabalin should be prescribed only for the treatment of neuropathic pain under the trademark LYRICA (Warner-Lambert Company, LLC v Actavis Group PTC EHF  EWHC 485 (Pat)). This effectively placed the doctors and pharmacists in the position of enforcing Warner-Lambert’s patent.
Could Australian doctors and pharmacists be compelled to enforce patents?
The judge in the UK Lyrica case noted that under current UK prescribing and dispensing practices, pharmaceuticals are almost always prescribed according to their generic name. The situation is likely the same in Australia. Further, pharmaceuticals are almost always prescribed without reference to the indication for which it is being prescribed (eg, see basic legislative requirements associated with writing prescriptions in the State of Victoria, Australia). Thus, while Australian courts might see skinny labelling as being sufficient to avoid infringement, the reality is that generics are likely to continue to be prescribed for patented indications.
Given the outcome of the UK Lyrica case, the question arises as to whether pharmaceutical originators will now seek court orders in Australia to have the Department of Health (the Australian equivalent of the NHS) issue guidance to prescribing and dispensing authorities to ensure that generics are not to be prescribed or issued to treat patented indications.
The author acknowledges the article "High Court orders NHS to give guidance on the prescribing of pregabalin in Warner-Lambert v Actavis", Christofer Freeth, Wragge Lawrence Graham & Co LLP, UK, for information on the UK Lyrica case.
This article first appeared in IAM magazine. For further information please visit www.iam-magazine.com.